URGN Q4 2021 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena

URGNUroGen Pharma Ltd.

$927M

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$16M+103.0% YoY

Gross Profit

$15M90.2% margin

Operating Income

-$20M-123.1% margin

Net Income

-$28M-175.9% margin

EPS (Diluted)

$-1.27

QoQ Revenue Growth

+42.5%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$20M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$120M

Total Liabilities

$111M

Stockholders' Equity

$8M

Cash & Equivalents

$44M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$16M	$8M	+103.0%
Gross Profit	$15M	$7M	+99.4%
Operating Income	-$20M	-$27M	+26.9%
Net Income	-$28M	-$31M	+6.8%

Revenue Segments

Jelmyto

$16M100%